Marc R Hammond
Overview
Explore the profile of Marc R Hammond including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
1885
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Freeman S, Sade-Feldman M, Kim J, Stewart C, Gonye A, Ravi A, et al.
Cell Rep Med
. 2022 Mar;
3(2):100500.
PMID: 35243413
Immune checkpoint blockade (CPB) improves melanoma outcomes, but many patients still do not respond. Tumor mutational burden (TMB) and tumor-infiltrating T cells are associated with response, and integrative models improve...
2.
Sade-Feldman M, Yizhak K, Bjorgaard S, Ray J, de Boer C, Jenkins R, et al.
Cell
. 2019 Jan;
176(1-2):404.
PMID: 30633907
No abstract available.
3.
Sade-Feldman M, Yizhak K, Bjorgaard S, Ray J, de Boer C, Jenkins R, et al.
Cell
. 2018 Nov;
175(4):998-1013.e20.
PMID: 30388456
Treatment of cancer has been revolutionized by immune checkpoint blockade therapies. Despite the high rate of response in advanced melanoma, the majority of patients succumb to disease. To identify factors...
4.
Zhang G, Wu L, Mender I, Barzily-Rokni M, Hammond M, Ope O, et al.
Clin Cancer Res
. 2018 Mar;
24(19):4771-4784.
PMID: 29563139
Telomerase promoter mutations are highly prevalent in human tumors including melanoma. A subset of patients with metastatic melanoma often fail multiple therapies, and there is an unmet and urgent need...
5.
Jenkins R, Aref A, Lizotte P, Ivanova E, Stinson S, Zhou C, et al.
Cancer Discov
. 2017 Nov;
8(2):196-215.
PMID: 29101162
systems that incorporate features of the tumor microenvironment and model the dynamic response to immune checkpoint blockade (ICB) may facilitate efforts in precision immuno-oncology and the development of effective combination...
6.
Sade-Feldman M, Jiao Y, Chen J, Rooney M, Barzily-Rokni M, Eliane J, et al.
Nat Commun
. 2017 Oct;
8(1):1136.
PMID: 29070816
Treatment with immune checkpoint blockade (CPB) therapies often leads to prolonged responses in patients with metastatic melanoma, but the common mechanisms of primary and acquired resistance to these agents remain...
7.
Vitiello M, Tuccoli A, DAurizio R, Sarti S, Giannecchini L, Lubrano S, et al.
Oncotarget
. 2017 Apr;
8(15):25395-25417.
PMID: 28445987
Despite increasing amounts of experimental evidence depicting the involvement of non-coding RNAs in cancer, the study of BRAFV600E-regulated genes has thus far focused mainly on protein-coding ones. Here, we identify...
8.
Lawrence N, Hammond M, Frederick D, Su Y, Dias-Santagata D, Deng A, et al.
J Am Acad Dermatol
. 2016 Aug;
75(3):595-602.
PMID: 27543214
Background: The prognostic role Ki-67, p53, and p16 immunostains and RET (rearranged during transfection) polymorphism in desmoplastic melanoma has not been evaluated. Objective: We sought to identify potential prognostic markers....
9.
Mochel M, Hammond M, Frederick D, Alora-Palli M, Piris A, Flaherty K, et al.
J Am Acad Dermatol
. 2015 Jul;
73(3):491-9.e2.
PMID: 26190239
Background: There are limited descriptions of histopathology and immune profiles of new or changing melanocytic nevi in the setting of B-Raf proto-oncogene (BRAF) inhibitor therapy. Objective: We sought to identify...